Editas Medicine, Inc. filings document regulatory disclosures for a clinical-stage genome editing company developing CRISPR-based in vivo medicines. Recent 8-K filings report operating results and financial condition, business highlights, EDIT-401 development disclosures, scientific data furnished under Regulation FD, and other events tied to CRISPR intellectual property matters.
The filing record also includes proxy materials covering board governance, executive compensation and equity awards, along with material-event reporting on a change in independent registered public accounting firm. These disclosures frame the company’s pipeline, capital resources, governance practices, risk areas and public-company reporting obligations.
Editas Medicine reported sharply improved 2025 results while pivoting to its in vivo gene-editing program EDIT-401. Full-year net loss narrowed to $160.1M, or $1.80 per share, from $237.1M, helped by lower research and development and general and administrative expenses tied to discontinuing its former reni-cel program.
Collaboration and other R&D revenue grew to $40.5M in 2025, supported by milestone and deferred revenue recognition. Cash, cash equivalents, and marketable securities were $146.6M as of December 31, 2025, and the company projects cash runway into the third quarter of 2027.
Lead candidate EDIT-401 reduced mean LDL cholesterol by more than 90% in non-human primates and is expected to have an IND/CTA submission by mid-2026, with a first-in-human HeFH trial planned later in 2026 and early human proof-of-concept data targeted by year-end 2026.
Editas Medicine CEO O'Neill Gilmore Neil reported an automatic tax-related share sale. On March 3, 2026, he sold 5,394 shares of Editas Medicine common stock in open-market transactions at a weighted average price of $2.0197 per share. The footnotes explain the sale was executed under a durable automatic sales instruction plan adopted on April 13, 2022 to cover tax withholding on restricted stock units that vested on March 2, 2026, and did not represent a discretionary trade. Following this transaction, he held 263,693 shares of common stock directly.
Editas Medicine, Inc. Senior Vice President and Chief Financial Officer Amy Parison reported an open-market sale of 474 shares of common stock at a weighted average price of $2.02 per share on March 3, 2026. According to the disclosure, the sale was executed under a durable automatic sales instruction plan adopted on July 7, 2022 and was made solely to cover tax withholding obligations arising from restricted stock units that vested on March 2, 2026, rather than as a discretionary trade. After this transaction, Parison directly owned 15,434 shares of Editas Medicine common stock.
Editas Medicine, Inc. executive Linda Burkly, EVP and Chief Scientific Officer, reported an open-market sale of 749 shares of common stock at a weighted average price of $2.0196 per share. After this transaction, she held 68,028 shares of Editas Medicine common stock.
According to the disclosure, the sale was carried out under a durable automatic sales instruction plan adopted on July 3, 2023 and was made to cover tax withholding obligations from restricted stock units that vested on March 2, 2026. The filing states that this was not a discretionary trade by the reporting person.
Gilmore O'Neill submitted a Form 144 reporting proposed and recent transactions in Common Stock. The filing lists 11,294 shares tied to a Restricted Stock Unit Vesting dated 03/02/2026 and a prior sale of 5,603 shares on 12/03/2025 for 12063.82.
Editas Medicine reported Q3 2025 results with collaboration revenue of $7.5 million driven by a BMS milestone. Operating expenses fell sharply after the 2024 program discontinuation, with R&D at $19.8 million and G&A at $12.3 million. The quarter’s operating loss was $24.5 million and net loss was $25.1 million, or $0.28 per share.
Cash and cash equivalents were $165.6 million, and management states existing cash is expected to fund operations into the third quarter of 2027. Year to date, the company recorded $66.9 million of restructuring and impairment charges tied to the wind-down of its ex vivo program, while interest expense reflects its sale of certain future Vertex-related payments. Common shares outstanding were 97,618,660 as of October 31, 2025.
The company raised $25.8 million net through its at-the-market equity program in the first nine months of 2025 and had $123.6 million of capacity remaining as of September 30, 2025. Authorized common stock increased to 390,000,000 shares. Editas is prioritizing in vivo programs, including EDIT-401 for LDL-C reduction.
Editas Medicine reported that it furnished a press release announcing financial results for the fiscal quarter ended September 30, 2025, along with other business highlights.
The press release was provided as Exhibit 99.1 and designated as furnished, not filed. The company’s common stock trades on Nasdaq under the symbol EDIT.
Editas Medicine, Inc. filed a report describing new preclinical data for EDIT-401, an experimental one-time gene-editing therapy designed to significantly reduce LDL-cholesterol by increasing LDL receptor levels. At a major gene and cell therapy congress, the company reported that in non-human primates a single dose of EDIT-401 led to LDL-C reductions equal to or exceeding 90% within 48 hours. Similar LDL-C reductions of at least 90% were also seen in mice with high baseline LDL-C and reduced LDL receptor function, with effects maintained over a three-month study. The therapy uses a CRISPR/Cas9 nuclease with dual guide RNAs delivered via lipid nanoparticles to disrupt negative regulatory elements in the 3’ UTR, which Editas says increased LDL receptor protein in primate liver by at least six-fold while requiring only moderate functional editing of LDLR alleles.
Linda C. Burkly, Executive Vice President and Chief Scientific Officer of Editas Medicine, reported a sale of 710 shares of the issuer's common stock on 09/03/2025 at a price of $2.5961 per share. The filing states the sale was effected under a durable automatic sales instruction plan adopted July 3, 2023, to satisfy tax withholding triggered by restricted stock units that vested on 09/02/2025, and the sale was not a discretionary trade. Following the transaction Burkly beneficially owns 69,490 shares, which includes 5,802 shares acquired under the company Employee Stock Purchase Plan.
Editas Medicine insider sale disclosed on Form 4: Amy Parison, SVP and Chief Financial Officer, reported a transaction dated 09/03/2025 showing the disposition of 458 shares of Editas Medicine common stock at a price of $2.5961 per share. After the sale, Ms. Parison beneficially owned 16,369 shares, held directly. The filing states the sale was effected under a durable automatic sales instruction plan adopted July 7, 2022, to satisfy tax withholding obligations tied to the vesting of restricted stock units on 09/02/2025, and that the sale was not a discretionary trade by the reporting person.